[
  {
    "ts": null,
    "headline": "Amgen Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Amgen Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=31a344e418beb1d9ccb29dd28a7a7b5c86a2bb3f966318e29ec2083f58d6b499",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733416740,
      "headline": "Amgen Inc. stock underperforms Thursday when compared to competitors",
      "id": 131876255,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=31a344e418beb1d9ccb29dd28a7a7b5c86a2bb3f966318e29ec2083f58d6b499"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth, Salesforce share losses contribute to Dow's 250-point drop",
    "summary": "UnitedHealth, Salesforce share losses contribute to Dow's 250-point drop",
    "url": "https://finnhub.io/api/news?id=306e39a5549ba4d1035b39dee58fd348fc9df4fd55c082937cdec55f69bdaa57",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733414160,
      "headline": "UnitedHealth, Salesforce share losses contribute to Dow's 250-point drop",
      "id": 131874493,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "UnitedHealth, Salesforce share losses contribute to Dow's 250-point drop",
      "url": "https://finnhub.io/api/news?id=306e39a5549ba4d1035b39dee58fd348fc9df4fd55c082937cdec55f69bdaa57"
    }
  },
  {
    "ts": null,
    "headline": "Boeing shares fall 1% as judge rejects plea deal",
    "summary": "Boeing shares fall 1% as judge rejects plea deal",
    "url": "https://finnhub.io/api/news?id=dc890aac33061863c312c796523ac67e2170c7ad1c1102adc3bda2bc9579e842",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733410809,
      "headline": "Boeing shares fall 1% as judge rejects plea deal",
      "id": 131874494,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Boeing shares fall 1% as judge rejects plea deal",
      "url": "https://finnhub.io/api/news?id=dc890aac33061863c312c796523ac67e2170c7ad1c1102adc3bda2bc9579e842"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA",
    "summary": "Amgen (NASDAQ: AMGN) today announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina. This brings the company's total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.",
    "url": "https://finnhub.io/api/news?id=8fdec8e9374dd6f181360c8a61e575dede7e7075f498949ad9ac07a2e782d461",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733407200,
      "headline": "AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA",
      "id": 131794978,
      "image": "https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ: AMGN) today announced a $1 billion expansion to establish a second drug substance manufacturing facility in North Carolina. This brings the company's total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.",
      "url": "https://finnhub.io/api/news?id=8fdec8e9374dd6f181360c8a61e575dede7e7075f498949ad9ac07a2e782d461"
    }
  },
  {
    "ts": null,
    "headline": "Is Amgen Still a Top Dividend Stock?",
    "summary": "The relationship between interest rates and dividend stocks tends to follow a predictable pattern.  Amgen (NASDAQ: AMGN) offers an intriguing test case for this dynamic heading into 2025.  In November, Amgen reported disappointing obesity-drug results.",
    "url": "https://finnhub.io/api/news?id=efe321a297c413dc00d4e03532ae035aefe27f0c4b887c95271af06c85b6e010",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733401680,
      "headline": "Is Amgen Still a Top Dividend Stock?",
      "id": 131794939,
      "image": "https://g.foolcdn.com/editorial/images/799868/dividends.jpg",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The relationship between interest rates and dividend stocks tends to follow a predictable pattern.  Amgen (NASDAQ: AMGN) offers an intriguing test case for this dynamic heading into 2025.  In November, Amgen reported disappointing obesity-drug results.",
      "url": "https://finnhub.io/api/news?id=efe321a297c413dc00d4e03532ae035aefe27f0c4b887c95271af06c85b6e010"
    }
  },
  {
    "ts": null,
    "headline": "LLY's Zepbound Outshines NVO's Wegovy in Head-to-Head Obesity Study",
    "summary": "LLY's obesity drug, Zepbound, shows an average weight loss of 20.2%, superior to 13.7% for NVO's Wegovy in a head-to-head study.",
    "url": "https://finnhub.io/api/news?id=75ed3ed21f0f469dc436389f3039a55902d53008f1d85bc9d1700cc34e6a1c05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733398320,
      "headline": "LLY's Zepbound Outshines NVO's Wegovy in Head-to-Head Obesity Study",
      "id": 131792048,
      "image": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "LLY's obesity drug, Zepbound, shows an average weight loss of 20.2%, superior to 13.7% for NVO's Wegovy in a head-to-head study.",
      "url": "https://finnhub.io/api/news?id=75ed3ed21f0f469dc436389f3039a55902d53008f1d85bc9d1700cc34e6a1c05"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Amgen, Eaton, Sony, iMage and Enzo Biochem",
    "summary": "Amgen, Eaton, Sony, iMage and Enzo Biochem are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=befec75bd30527e448d37b1bb6bcf2634b6aec29a279a7005f3297a81d6d7d62",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733392800,
      "headline": "The Zacks Analyst Blog Highlights Amgen, Eaton, Sony, iMage and Enzo Biochem",
      "id": 131792394,
      "image": "https://media.zenfs.com/en/zacks.com/6d46ed8fcc6d04a0d687ddd317d1fb0b",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen, Eaton, Sony, iMage and Enzo Biochem are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=befec75bd30527e448d37b1bb6bcf2634b6aec29a279a7005f3297a81d6d7d62"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Plans $1 Billion North Carolina Manufacturing Plant",
    "summary": "By Colin Kellaher Amgen on Thursday unveiled plans to spend $1 billion on a second drug-substance manufacturing plant in Holly Springs, N.C., boosting its total planned investment in the town to...",
    "url": "https://finnhub.io/api/news?id=4214b85518559da62e8daf3a3da94a3a8b662170b1a6b18e89f5c01c9701259b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733392028,
      "headline": "Amgen Plans $1 Billion North Carolina Manufacturing Plant",
      "id": 131791768,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Amgen on Thursday unveiled plans to spend $1 billion on a second drug-substance manufacturing plant in Holly Springs, N.C., boosting its total planned investment in the town to...",
      "url": "https://finnhub.io/api/news?id=4214b85518559da62e8daf3a3da94a3a8b662170b1a6b18e89f5c01c9701259b"
    }
  },
  {
    "ts": null,
    "headline": "Update On Pending Denosumab BPCIA Litigations",
    "summary": "There are four pending BPCIA litigations brought by Amgen against biosimilar companies seeking to market denosumab biosimilars. Two of the four cases are pending in the District Court for the District...",
    "url": "https://finnhub.io/api/news?id=88c70eb0bea868293a52141c5ae57e709f38f3c96234a08fc730d2fc47dabcee",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733361311,
      "headline": "Update On Pending Denosumab BPCIA Litigations",
      "id": 131774399,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "There are four pending BPCIA litigations brought by Amgen against biosimilar companies seeking to market denosumab biosimilars. Two of the four cases are pending in the District Court for the District...",
      "url": "https://finnhub.io/api/news?id=88c70eb0bea868293a52141c5ae57e709f38f3c96234a08fc730d2fc47dabcee"
    }
  }
]